Home > Insider Trading > Filing (0001567619-21-000102)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1628171	Revolution Medicines Inc.	RVMD	Biological Products, (No Disgnostic Substances) (2836)	472029180

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1800670	Barbara Weber	C/O Revolution Medicines, Inc. 700 Saginaw Drive Redwood City CA 94063		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2020-12-30	5,336	$1.12	7,144	No	4	M	Direct
Common Stock	Disposition	2020-12-30	5,236	$40.95	1,908	No	4	S	Direct
Common Stock	Disposition	2020-12-30	100	$41.33	1,808	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2020-12-30	5,336	$0.00	5,336	$1.12

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
13,489		2028-04-19	No	4	M	Direct

Footnotes

Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
Includes 1,808 Restricted Stock Units.
The transaction was executed in multiple trades in prices ranging from $40.27 to $41.17, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
This option is early exercisable. Twenty-five percent of the total shares subject to the option vested on the first anniversary measured from April 20, 2018 (the "Vesting Commencement Date") and one sixteenth (1/16th) of the shares subject to the option will vest quarterly thereafter, so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each such vesting date.